US Patent No. 6,630,507 Update: The People Have Spoken!

 

U.S. Patent 6,630,507 Is Now Expired For Life!

​

​

​

​

​

​

​

 

 

The U.S. government held Patent No. 6,630,507 until 2019 but continued to operate and hide the true status of the patent until 2021/2022. And for obvious reasons, the USPTO did not list or publicize the new status. Public outcry had a great influence on creating awareness as to the injustice and outright hypocrisy of the patent being held.  This allowed for The National ConsensUS Party

(The People's Official House ), to publicly announce its campaign challenging the patent as a Presidential Electoral Party.

 

The results are the USPTO publicly updateing the patent status.

​

UP Next - Descheduling The Plant:

​

With the success of the US Patent update, Descheduling is now within reach!

​

In the United States, the removal of cannabis from Schedule I of the Controlled Substances Act, the most tightly restricted category reserved for drugs that have "no currently accepted medical use,” has been proposed repeatedly since 1972. Descheduling proponents argue that cannabis does not meet the Controlled Substances Act's strict criteria for placement in Schedule I and so the government is required by law to permit medical use or to remove the drug from federal control altogether. The US government, on the other hand, maintains that cannabis is dangerous enough to merit Schedule I status. The dispute is based on differing views on both how the Act should be interpreted and what kinds of scientific evidence are most relevant to the rescheduling decision.

​

A US judge says in a DEA concurring opinion that the agency may soon be forced to consider a policy change anyway based on a misinterpretation of the medical value of cannabis (referring to both Former U.S. Patent 6630507 and DEA public information).

​

​

​